Portal de investigación
Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Carrato A
- Gómez A
- Escudero P
- Chaves M
- Rivera F
- Marcuello E
- González E
- Grávalos C
- Constenla M
- Manzano JL
- Losa F
- Maurel J
- Dueñas R
- Massuti B
- Gallego J
- Aranda E
Grupos
Abstract
To evaluate the efficacy and safety profile of the combination of panitumumab and irinotecan every 3 weeks in a phase II trial as second-line treatment in patients with advanced wild-type (WT) K-RAS colorectal cancer (CRC).
Datos de la publicación
- ISSN/ISSNe:
- 1699-048X, 1699-3055
- Tipo:
- Article
- Páginas:
- 705-711
- PubMed:
- 23359181
- Factor de Impacto:
- 0,589 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
Clinical & Translational Oncology SPRINGER INT PUBL AG
Citas Recibidas en Web of Science: 8
Documentos
- No hay documentos
Filiaciones
Campos de Estudio
Cita
Carrato A,Gómez A,Escudero P,Chaves M,Rivera F,Marcuello E,González E,Grávalos C,Constenla M,Manzano JL,Losa F,Maurel J,Dueñas R,Massuti B,Gallego J,APARICIO J,ANTÓN A,Aranda E. Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. Clin. Transl. Oncol. 2013. 15. (9):p. 705-711. IF:1,600. (4).